Brought to you by 
Ipsen, Tercica cross-license endocrine compounds
23 Aug 2006
Executive Summary
In a 15-year deal, French pharma giant Ipsen and Tercica (therapeutics for metabolic disorders) are cross-licensing two products: Ipsen's Somatuline Autogel sustained-release injectable lanreotide for acromegaly and Tercica's Increlex mecasermin injection for growth failure in children.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen, Tercica cross-license endocrine compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice